The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Active agent delivery systems and methods for protecting and administering active agents

A sustained-release preparation applicable to mucous membrane in oral cavity which comprises an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight, and optionally in admixture with conventional carrier and additives Said preparation may be formed in the form of a two-layer preparation with a layer comprising an active ingredient and one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and optionally in admixture with conventional carrier and additives The preparation can easily be adhered to mucous membrane within oral cavity and maintained for a long period of time and the medicament (eg nifedipine) contained therein is released into saliva continuously to exhibit the activity effectively

Sustained-release preparation applicable to mucous membrane in oral cavity

The present invention is a saccharide-based matrix, and the products resulting therefrom, made from a maltodextrin feedstock subjected to conditions which induce flash flow of the maltodextrin so that the matrix possesses a physically or chemically altered structure from the feedstock. The present invention also includes a method of producing the matrix and of making products which take advantage of the unique properties of the matrix.

Saccharide-based matrix

Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.

Sustained release heterodisperse hydrogel systems--amorphous drugs

A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

Sustained release heterodisperse hydrogel systems for insoluble drugs

The invention is directed to the provision of solid pharmaceutical compositions (and methods for their preparation) containing nifidipine crystals with a specific surface area of 1.0 to 4.0 m2 /g., in admixture with a solid diluent. The said compositions overcome the deficiencies of prior art compositions containing nifidipine, which is known to have effect as a coronary vasodilator.

Solid medicament formulations containing nifedipine, and processes for their preparation

Solid dihydropyridines, e.g. nifedipine and nimodipine preparations having a maximum standard deviation of the active compound content of 3% contain 1 part by weight of nifedipine, 2 to 6 parts by weight of PVP with a mean molecular weight of 15,000 to 50,000, 3.5 to 15 parts by weight of cellulose, 0.25 to 4 parts by weight of starch and 0.5 to 4 parts by weight of cross-linked insoluble PVPP, and, if appropriate, one or more further pharmaceutical auxiliaries and excipients. These preparations show a good release of dihydropyridine with good content uniformity.

Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

1. A solid pharmaceutical composition containing as the active ingredient nifedipine crystals with a specific surface area of 0,5 to 6 m**2 /g, in admixture with a solid diluent.

Solid pharmaceutical compositions containing nifedipine, and process for their preparation

The present invention relates to special rapidly absorbable solid medicinal preparations which contain dihydropyridines and polyvinylpyrroldione and to processes for their preparation.

Process for preparing solid fast-releasing drug formulations of dihydropyridines

The invention relates to a combination of β-carotene and iron oxides as lightfast, opaque colorant of gelatin and their use in foods and pharmaceuticals, in particular in the shell of soft gelatin capsules.

Ahmed Dr. Hegasy

Papers

Solid medicament formulations containing nifedipine, and processes for their preparation

Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

Solid pharmaceutical compositions containing nifedipine, and process for their preparation

Process for preparing solid fast-releasing drug formulations of dihydropyridines

Gelatin containing beta-carotene